KA/EN
Register
Medicines reference
Search
Search
Active substance

Polystyrene sulfonate sodium

Favourites

Sulfonated polymer. Not applicable (not a medicine). Forms: gel.

Dose and use

Doses

We have no dose with a cited source for this substance yet.

Before use

Safety information

No sourced safety entry is currently shown. This does not mean the substance is risk-free.

Latin name
Polystyrene sulfonate sodium
Georgian name
პოლისტირენ-სულფონატი ნატრიუმის
Authorisation status
Complementary feed / supplement
Not a medicine and not required to be authorised as one - it is sold under feed law.
Registered in Georgia
0 of 1 forms
Products
Acatavir
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration1

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Acatavir, Gel

oral gel 30 ml, VetExpert
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
5.1/10
Weak evidence support
vetman assessment

Acatavir

oral gel 30 ml, VetExpert
Assessed clinical scopeCat · Supportive local oral-mucosal use during or after feline viral upper-respiratory/oral disease; strongest evidence is FCV-positive chronic oral inflammation after dental care, while FHV support remains in-vitro · On the skin
Care settingVeterinarian-directed clinic/home gingival adjunct after diagnosis, with dental/supportive care, pain and nutrition assessment, exact pump-site instruction and four-week reassessment.
vetman score 5.1/10 Weak evidence support
Evidence confidence: Medium Georgia: Not a medicine · Verified on 22 Oct 2026

A genuinely studied local PSSNa concept with a small controlled FCV cat trial, but the commercial concentration is undisclosed and evidence does not yet support broad FCV/FHV, regeneration or standalone-treatment claims.

Regulatory and scientific credibility4.0/10

Exact product, INCI, device directions and linked studies are traceable, but no medicine dossier exists, PSSNa concentration/pump mass are undisclosed and the only clinical evidence is sponsor-linked without independently auditable commercial-to-study quantitative equivalence; the evidence gate therefore caps this axis at 4.0.

Clinical efficacy4.0/10

A small randomised double-blind placebo-controlled FCV field study supports a four-week local adjunct signal, but concurrent dental care, both-group viral decline, unchanged Oral Health Index, short follow-up, strain nonresponse, patent conflicts, sponsor linkage, unverified commercial-form equivalence and almost no FHV clinical data trigger the 4.0 evidence ceiling.

Safety and tolerability6.0/10

No adverse effects occurred in 14 PSSNa-treated cats over four weeks and formulation testing adds reassurance, but uncommon, long-term, repeat-course, kitten, reproductive, severe-disease, aspiration and excipient risks are not characterised.

Clinical practicality7.0/10

The silent pump and adherent local gel are workable once or twice daily, but painful oral disease can make restraint stressful and one pump is not a disclosed volume or PSSNa mass; eye/nasal delivery is inappropriate.

Full-course cost-effectiveness-

No verified current Georgian patient-adjusted four-week course price is available, so cost is excluded.

Important safety and use flags

  • Local oral-support gel, not a systemic antiviral medicine or complementary feed. Medicine-authorisation status is not applicable and does not imply regulator-reviewed efficacy or safety.
  • Adjunct only. Continue diagnosis-specific dental care, analgesia, hydration/nutrition, infection control and treatment of ocular, respiratory, systemic or secondary bacterial disease as indicated.
  • The controlled field signal applies to 28 FCV-positive cats with chronic oral inflammation after standard dental treatment. It does not establish standalone treatment, prevention, transmission control, severe systemic FCV care or durable recurrence benefit.
  • FHV-1 support is based on in-vitro entry inhibition; only four FHV-positive cats were available in the field population. Do not claim clinical FHV efficacy or replace established ocular/systemic care.
  • Acatavir PSSNa concentration and mass/volume per pump are not public. The study used sterile formulation no. 3 as two drops once daily; commercial one-pump/site once- or twice-daily quantitative equivalence is not independently auditable.
  • Several trial authors were affiliated with Acatavir Ltd, and use of PSSNa for cat flu is patented to co-authors. Treat the small positive trial as preliminary despite randomisation and blinding.
  • For gingival/oral-mucosal use only. Do not apply to eyes or nose and do not improvise systemic, ophthalmic or intranasal delivery; the commercial gel is not an ophthalmic product.
  • No adverse effects in 14 treated cats over four weeks cannot establish uncommon or long-term safety. Monitor oral irritation, hypersalivation, swallowing/aspiration, vomiting, appetite, pain, restraint stress and excipient sensitivity.
  • Reassess at about four weeks with clinical oral examination and, when clinically meaningful, FCV/FHV testing. Stop earlier for deterioration, no tolerable administration or need for escalation.
  • Exact safety in kittens, pregnancy, lactation, breeding cats, severe systemic disease and repeated or long-term courses is not established; use only after explicit individual benefit-risk review.
Assessment sources
  1. VetExpert Acatavir2026
  2. Acatavir monograph2026
  3. PSSNa feline field RCT2026
  4. PSSNa in-vitro study2019
  5. FCV clinical review2022
  6. FCV 2024 update2024
  7. ABCD FHV guideline2026
  8. ISCAID respiratory guideline2017
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Polystyrene sulfonate sodium
Formulation Type
Gel
Administration route
On the skin
Manufacturer
Vet Planet Sp. z o.o. (VetExpert) · Poland
Registration
Georgia Not a medicine
Not applicable (not a medicine)
Verified on: 22 Oct 2026
 EU Not a medicine
Not applicable (not a medicine)
Verified on: 22 Oct 2026
 UK Not a medicine
Not applicable (not a medicine)
Verified on: 22 Oct 2026
 US Not a medicine
Not applicable (not a medicine)
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified Shake before use. Apply a small amount locally to affected gingiva/oral mucosa and gently spread; no more than one pump at one application site, once or twice daily under veterinary direction. The field study used two drops once daily for 28 days. PSSNa concentration and pump mass are unpublished, so neither schedule is a transferable mg dose.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗